Free Trial
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel
NASDAQ:SVRA

Savara Q3 2026 Earnings Date & Estimates

Savara logo
$4.76 -0.02 (-0.42%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$5.00 +0.24 (+5.00%)
As of 06:33 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Savara is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, after market closes. The conference call is scheduled for 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Savara in Q3 2026

Savara is expected to post earnings of -$0.1633 per share on revenue of $0.50 million. In the same quarter a year earlier Savara reported -$0.14 per share. Savara last reported on August 11, 2026, posting -$0.16 per share and missing the -$0.1413 consensus estimate. Savara has beaten the consensus EPS estimate in 0 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.1633
Expected Revenue
$0.50 million
Prior-Year EPS
-$0.14

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.16 (Missed by -$0.0188)
EPS Beat Rate
0 of last 8 quarters

Prepare for the Q3 2026 Call

Savara Q3 2026 Earnings FAQ

Savara (NASDAQ:SVRA) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Savara's Q3 2026 earnings conference call is scheduled for Wednesday, November 11, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Savara to post earnings of -$0.1633 per share for Q3 2026.

The consensus revenue estimate for Savara is $0.50 million for Q3 2026.

Savara Earnings Headlines

Will Long‑Term Molgramostim Data at CHEST 2026 Change Savara's (SVRA) Autoimmune PAP Narrative?
October 13 at 12:08 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/long-term-molgramostim-data-chest-081402561.html
Savara Inc. (SVRA) - What Are Analysts Thinking About This Stock?
October 13 at 4:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31114066
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.tc pixel
October 15 at 1:00 AM  |  Investors Alley (Ad)
Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026
October 12 at 4:05 PM  |  businesswire.comhttps://www.businesswire.com/news/home/20261012229402/en/savara-to-present-new-analysis-from-the-impala-clinical-trial-and-deliver-encore-presentation-of-long-term-data-on-molgramostim-in-autoimmune-pulmonary-alveolar-proteinosis-apap-at-chest-2026/
Savara (NASDAQ:SVRA) Now Covered by Analysts at JPMorgan Chase & Co.
October 8, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31098301
JPMorgan Initiates Savara at Overweight With $12 Price Target
October 7, 2026  |  marketscreener.comM
See More Savara Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Savara? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Savara and other key companies, straight to your email.

About Savara

Savara (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases. The company’s lead product candidate is molgramostim, an inhaled formulation of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) being developed for autoimmune pulmonary alveolar proteinosis (aPAP), a rare disorder in which surfactant accumulates in the lungs and impairs breathing.

Savara has conducted clinical development activities in the United States and internationally, including Europe. The company’s research and development strategy is centered on advancing therapies for serious pulmonary conditions with limited treatment options. Molgramostim is an investigational product and its availability and regulatory status may vary by jurisdiction.

Savara is headquartered in Austin, Texas, and is led by Chief Executive Officer Matthew Pauls. The company’s history includes a focus on rare respiratory diseases and the development of inhaled therapies intended to address underlying disease mechanisms rather than solely manage symptoms.

View Savara Profile
Earnings Tools